1. Home
  2. MLTX vs MGNI Comparison

MLTX vs MGNI Comparison

Compare MLTX & MGNI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MLTX
  • MGNI
  • Stock Information
  • Founded
  • MLTX 2021
  • MGNI 2007
  • Country
  • MLTX Switzerland
  • MGNI United States
  • Employees
  • MLTX N/A
  • MGNI N/A
  • Industry
  • MLTX Biotechnology: Pharmaceutical Preparations
  • MGNI Computer Software: Programming Data Processing
  • Sector
  • MLTX Health Care
  • MGNI Technology
  • Exchange
  • MLTX Nasdaq
  • MGNI Nasdaq
  • Market Cap
  • MLTX 2.8B
  • MGNI 3.1B
  • IPO Year
  • MLTX N/A
  • MGNI N/A
  • Fundamental
  • Price
  • MLTX $51.18
  • MGNI $23.85
  • Analyst Decision
  • MLTX Strong Buy
  • MGNI Strong Buy
  • Analyst Count
  • MLTX 7
  • MGNI 12
  • Target Price
  • MLTX $74.83
  • MGNI $25.75
  • AVG Volume (30 Days)
  • MLTX 732.8K
  • MGNI 3.0M
  • Earning Date
  • MLTX 11-06-2025
  • MGNI 11-06-2025
  • Dividend Yield
  • MLTX N/A
  • MGNI N/A
  • EPS Growth
  • MLTX N/A
  • MGNI N/A
  • EPS
  • MLTX N/A
  • MGNI 0.29
  • Revenue
  • MLTX N/A
  • MGNI $685,074,000.00
  • Revenue This Year
  • MLTX N/A
  • MGNI $3.71
  • Revenue Next Year
  • MLTX N/A
  • MGNI $12.33
  • P/E Ratio
  • MLTX N/A
  • MGNI $84.61
  • Revenue Growth
  • MLTX N/A
  • MGNI 5.52
  • 52 Week Low
  • MLTX $31.42
  • MGNI $8.22
  • 52 Week High
  • MLTX $61.87
  • MGNI $26.65
  • Technical
  • Relative Strength Index (RSI)
  • MLTX 38.79
  • MGNI 49.24
  • Support Level
  • MLTX $51.45
  • MGNI $22.23
  • Resistance Level
  • MLTX $61.30
  • MGNI $24.50
  • Average True Range (ATR)
  • MLTX 2.88
  • MGNI 1.22
  • MACD
  • MLTX -0.85
  • MGNI -0.25
  • Stochastic Oscillator
  • MLTX 3.08
  • MGNI 36.65

About MLTX MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients.

About MGNI Magnite Inc.

Magnite Inc is one of the supply-side platform providers, or SSP, in online advertising. The firm generate its revenue from the programmatic sale of CTV ad inventory, from mobile online sites and apps, and the remaining from websites accessed via computer.

Share on Social Networks: